X

Trial Profile

Allogeneic non-myeloablative stem cell transplantation utilizing mis-matched family member stem cells purged using campath-1H [alemtuzumab].

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine; Granulocyte colony-stimulating factors
Indications Cancer; Graft-versus-host disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Feb 2012 Planned end date changed from 1 Feb 2010 to 1 Feb 2015 as reported by ClinicalTrials.gov.
27 Feb 2008 Status change from recruiting to in progress.
16 Jan 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com